Ascorbic acid high dose therapy
Pro Research Analysisby 
Searched over 200M research papers
High-Dose Ascorbic Acid Therapy: Safety and Tolerability
Several studies have evaluated the safety of high-dose ascorbic acid (vitamin C) therapy, particularly when administered intravenously. Clinical trials in patients with advanced cancer have shown that high-dose intravenous ascorbic acid is generally well tolerated, with minimal adverse effects reported across various dosing regimens, including doses up to 110 g/m² and 1.5 g/kg three times weekly 210. These studies did not observe significant toxicity, suggesting that high-dose ascorbic acid can be safely administered in a controlled clinical setting 210.
High-Dose Ascorbic Acid in Cancer Therapy
Lack of Objective Anticancer Response as Monotherapy
Despite its safety, high-dose ascorbic acid as a single agent has not demonstrated objective anticancer responses in patients with advanced malignancies. Multiple phase I trials found no significant tumor regression or clinical benefit when ascorbic acid was used alone, although the therapy was well tolerated 210. Reviews of the literature also highlight the controversial and inconclusive history of vitamin C in cancer treatment, emphasizing the need for further research and optimized protocols .
Synergy with Immunotherapy
Recent preclinical studies have shown that high-dose ascorbic acid may enhance the effectiveness of immune checkpoint inhibitors, such as anti-PD1 therapy. In mouse models of lymphoma and non-small cell lung cancer, high-dose ascorbic acid increased the infiltration and activity of cytotoxic T cells and macrophages within tumors, leading to greater tumor inhibition when combined with anti-PD1 agents compared to either treatment alone 35. These findings suggest that high-dose ascorbic acid could be a promising adjuvant to immunotherapy, potentially improving outcomes in certain cancers 35.
High-Dose Ascorbic Acid in Sepsis and Critical Illness
High-dose ascorbic acid has shown potential benefits in critically ill patients, particularly those with septic shock. Clinical studies in surgical ICU patients found that high-dose intravenous ascorbic acid reduced the need for vasopressor drugs, shortened the duration of vasopressor use, and was associated with lower 28-day mortality compared to placebo . Experimental models of sepsis further demonstrated that high-dose ascorbic acid can modulate immune responses, reduce organ dysfunction, and inhibit key inflammatory pathways, such as STAT1 phosphorylation and PD-L1 expression . These results indicate that high-dose ascorbic acid may be an effective and safe adjunctive therapy in sepsis, though optimal dosing and timing require further investigation 69.
Other Clinical and Preclinical Applications
Hematologic Disorders
A phase II trial in patients with TET2-mutant clonal cytopenia of undetermined significance (CCUS) found that high-dose intravenous ascorbic acid was safe but did not produce clinical responses by standard criteria .
Radioprotection
In animal studies, high-dose ascorbic acid administered after radiation exposure significantly improved survival and reduced radiation-induced damage, suggesting a potential role as a radioprotectant .
Potential Risks
There are case reports indicating that high-dose ascorbic acid may have adverse effects in certain populations. For example, a patient with sickle cell thalassemia experienced repeated sickle cell crises after using high-dose ascorbic acid, with no further crises after discontinuation, highlighting the need for caution in specific patient groups .
Conclusion
High-dose ascorbic acid therapy is generally safe and well tolerated in clinical settings, with promising roles as an adjunct in cancer immunotherapy and sepsis management. While it has not shown significant anticancer effects as a monotherapy, its ability to enhance immune responses and reduce inflammation in preclinical and clinical studies supports further investigation, particularly in combination with other treatments. However, potential risks exist for certain patient populations, and optimal dosing strategies remain to be defined.
Sources and full results
Most relevant research papers on this topic